Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 25 cents a share - Earnings Preview

Reuters11-09

* Reviva Pharmaceuticals Holdings, Inc.

is expected to show no change in quarterly revenue when it reports results on November 12 (estimated) for the period ending January 1 0001

*

* LSEG's mean analyst estimate for Reviva Pharmaceuticals Holdings, Inc. is for a loss of 25 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings, Inc. is $15.00, above its last closing price of $0.94.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.29 -0.29 -0.26 Beat 10.3

Mar. 31 2024 -0.36 -0.38 33.6

Dec. 31 2023 -0.35 -0.35 Met 0.7

Sep. 30 2023 -0.43 -0.37 -0.44 Missed -20.2

Jun. -0.31 -0.28 -0.55 Missed -99.3

30 2023

Jan. 1 0001 -0.32 -0.32 -0.30 Beat 7.7

Dec. 31 2022 -0.19 -0.22 -0.38 Missed -72.7

Sep. 30 2022 -0.28 -0.29 -0.18 Beat 37.2

This summary was machine generated November 8 at 16:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482148517?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482148517","market":"us","top_or_hot":-1,"title":"Reviva Pharmaceuticals Holdings, Inc.    expected to post a loss of 25 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/RVPH\">Reviva Pharmaceuticals Holdings, Inc.</a>   </p><p>  is expected to show no change in quarterly revenue when it reports  results on November 12 (estimated) for the period ending January 1 0001</p><p>   * </p><p>   * LSEG's mean analyst estimate for Reviva Pharmaceuticals Holdings, Inc. is for a loss of 25 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings, Inc. is $15.00, above its last closing price of $0.94. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.29       -0.29      -0.26     Beat    10.3</p><p>Mar. 31 2024  -0.36       -0.38                        33.6</p><p>Dec. 31 2023              -0.35      -0.35     Met     0.7</p><p>Sep. 30 2023  -0.43       -0.37      -0.44     Missed  -20.2</p><p>Jun.        -0.31       -0.28      -0.55     Missed  -99.3</p><p>30 2023                                                </p><p>Jan. 1 0001   -0.32       -0.32      -0.30     Beat    7.7</p><p>Dec. 31 2022  -0.19       -0.22      -0.38     Missed  -72.7</p><p>Sep. 30 2022  -0.28       -0.29      -0.18     Beat    37.2</p><p>This summary was machine generated November 8 at 16:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reviva Pharmaceuticals Holdings, Inc.    expected to post a loss of 25 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReviva Pharmaceuticals Holdings, Inc.    expected to post a loss of 25 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 00:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Reviva Pharmaceuticals Holdings, Inc.   is expected to show no change in quarterly revenue when it reports  results on November 12 (estimated) for the period ending January 1 0001   *    * LSEG's ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVPH","symbol_name":"Reviva Pharmaceuticals Holdings, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2482148517","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482148517","pubTimestamp":1731081748,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Reviva Pharmaceuticals Holdings, Inc.     is expected to show no change in quarterly revenue when it reports  results on November 12 (estimated) for the period ending January 1 0001   *    * LSEG's ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"translate_title":"Reviva Pharmaceuticals Holdings,Inc.预计每股亏损25美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVPH":1},"content_text":"* Reviva Pharmaceuticals Holdings, Inc.   is expected to show no change in quarterly revenue when it reports  results on November 12 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst estimate for Reviva Pharmaceuticals Holdings, Inc. is for a loss of 25 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings, Inc. is $15.00, above its last closing price of $0.94. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.29       -0.29      -0.26     Beat    10.3Mar. 31 2024  -0.36       -0.38                        33.6Dec. 31 2023              -0.35      -0.35     Met     0.7Sep. 30 2023  -0.43       -0.37      -0.44     Missed  -20.2Jun.        -0.31       -0.28      -0.55     Missed  -99.330 2023                                                Jan. 1 0001   -0.32       -0.32      -0.30     Beat    7.7Dec. 31 2022  -0.19       -0.22      -0.38     Missed  -72.7Sep. 30 2022  -0.28       -0.29      -0.18     Beat    37.2This summary was machine generated November 8 at 16:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482148517"}